Surterra Wellness announced that William "Beau" Wrigley, Jr. has joined Surterra's Board of Directors as Chairman. Additionally, Surterra Wellness closed a $65 million Series C equity fundraising round in July, led by Wrigley's direct investment arm. The round brings Surterra's total capital raised to over $100 million since 2015.

Speaking for the first time publicly about his investment, Wrigley said, "I am thrilled to join the Surterra team and help drive their mission to build a best-in-class cannabis healthcare business. After extensive diligence, we determined that Surterra has the highest quality standards, best products, and most professional management team in the industry. We believe in the ability of cannabis to improve quality of life for patients across the country, and we are excited to build a global industry leader for the long term."

Beau led the Wm. Wrigley Jr. Company, a global leader in confections founded in 1891, by serving in multiple roles, including Chairman, President and CEO. During his leadership, the Wrigley Company expanded its product portfolio through numerous acquisitions including Altoids and LifeSavers as well as organic growth, reaching consumers in 180 countries. In 2008, the Wrigley Company was sold to privately held Mars, Incorporated. Currently, Beau is President of Wychwood Asset Management LLC, an investment company that invests in a range of venture capital and private equity interests. Additionally, Beau serves on several boards of high-growth companies across the technology, media, and health and wellness spaces.

"Surterra is proud to welcome Beau, a business leader who brings decades of world class experience and expertise in brand building, to Surterra Wellness," said Surterra CEO Jake Bergmann. "Having a seasoned industry veteran like Beau intimately involved in building Surterra's business is exciting for the future of Surterra, our patients and the entire medical cannabis industry."

Concurrent to joining Surterra as Chairman of the Board, Wrigley led a $65 million "Series C" direct equity investment in Surterra Holdings, Inc.  Surterra plans on using the funds across a number of strategic initiatives in Florida and Texas. Plans include constructing substantial cultivation space in Florida, executing multiple partnerships with premier consumer brands, and accelerating its product development initiatives. In addition, Surterra will conduct clinical research trials related to cannabinoid treatment of anxiety, pain, and PTSD, as well as other significant health issues facing the country, with cannabinoids.

The company will also expand into new state markets across the country as it builds the industry's broadest portfolio of brands trusted by patients.